Hypercholesterolemia

• 

  Subject Areas on Research

  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. 
  • A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits. 
  • A protocol to evaluate the efficacy, perceptions, and cost of a cholesterol packaging approach to improve medication adherence. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. 
  • Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. 
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
  • An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. 
  • Analyses of cancer data from three ezetimibe trials. 
  • Angiotensin II mobilizes spleen monocytes to promote the development of abdominal aortic aneurysm in Apoe-/- mice. 
  • Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. 
  • Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events. 
  • Application of new cholesterol guidelines to a population-based sample. 
  • Application of the new cholesterol guidelines. 
  • Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Benefits of Bempedoic Acid - Clearer Now. 
  • Calcium-activated potassium channels mask vascular dysfunction associated with oxidized LDL exposure in rabbit aorta. 
  • Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Characteristics and Correlates of Metabolic Syndrome in Adolescents with Unipolar and Bipolar Depression: Results from a Cross-National Inpatient Case-Control Study. 
  • Cholesterol feeding reduces vascular endothelial growth factor signaling in rabbit corporal tissues. 
  • Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. 
  • Cholesterol-lowering medication and relapse of depression. 
  • Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study. 
  • Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. 
  • Culturally-sensitive weight loss program produces significant reduction in weight, blood pressure, and cholesterol in eight weeks. 
  • Differentiating Behavior Initiation and Maintenance: Theoretical Framework and Proof of Concept. 
  • Discontinuation of statins in routine care settings. 
  • Do healthy adults need to know their cholesterol level? 
  • Does a high level of HDL-C cholesterol undo the bad effects of a high LDL-C cholesterol? 
  • Effect of Alirocumab on Mortality After Acute Coronary Syndromes. 
  • Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. 
  • Effect of hypercholesterolemia on transendothelial EBD-albumin permeability and lipid accumulation in porcine iliac arteries. 
  • Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS). 
  • Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. 
  • Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. 
  • Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. 
  • Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. 
  • Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. 
  • Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. 
  • Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. 
  • Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. 
  • Estimating lifetime risk of developing high serum total cholesterol: adjustment for baseline prevalence and single-occasion measurements. 
  • Evaluation of a packaging approach to improve cholesterol medication adherence. 
  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
  • Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. 
  • Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. 
  • Failure of red blood cell maturation in mice with defects in the high-density lipoprotein receptor SR-BI. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Frequency of hypothyroidism in adults with serum total cholesterol levels > 200 mg/dl. 
  • Gastric xanthomatosis and cholestasis. A causal relationship. 
  • Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance. 
  • Health beliefs and desire to improve cholesterol levels among patients with hyperlipidemia. 
  • Heart disease and stroke statistics--2011 update: a report from the American Heart Association. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • Heterozygous ABCG5 Gene Deficiency and Risk of Coronary Artery Disease. 
  • High prevalence of low HDL-c in the Philippines compared to the US: population differences in associations with diet and BMI. 
  • Hypercholesterolemia Increases Colorectal Cancer Incidence by Reducing Production of NKT and γδ T Cells from Hematopoietic Stem Cells. 
  • Hypercholesterolemia and prostate cancer: a hospital-based case-control study. 
  • Hypercholesterolemia in rats with chronic renal insufficiency not aggravated by recombinant human growth hormone. 
  • Hypercholesterolemia induces oxidant stress that accelerates the ageing of hematopoietic stem cells. 
  • Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. 
  • Hypercholesterolemia paradox in relation to mortality in acute coronary syndrome. 
  • Identification of genetic defect of an epilepsy: strategies for therapeutic advances. 
  • Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer. 
  • Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Impact of Secondary Prevention in an Occupational High-Risk Group. 
  • Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. 
  • Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. 
  • Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. 
  • Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. 
  • Increasing Stroke Knowledge and Decreasing Stroke Risk in a Latino Immigrant Population. 
  • Inflammation biomarkers and near-term death in older men. 
  • Inhibition of NADPH oxidase by apocynin attenuates progression of atherosclerosis. 
  • Inhibition of p38 Mitogen-Activated Protein Kinase Enhances the Apoptosis Induced by Oxidized Low-Density Lipoprotein in Endothelial Progenitor Cells. 
  • Interventions to Improve Statin Tolerance and Adherence in Patients at Risk for Cardiovascular Disease : A Systematic Review for the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Guidelines for Management of Dyslipidemia. 
  • Juvenile acute intermittent porphyria with hypercholesterolemia and epilepsy: a case report and review of the literature. 
  • L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. 
  • L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. 
  • Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. 
  • Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. 
  • Malakoplakia of the prostate on needle core biopsy: a case report and review of the literature. 
  • Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. 
  • Management of cardiovascular risk in the usual care of Medicaid recipients. 
  • Mechanism of the interaction of hypertension and hypercholesterolemia in atherogenesis: the effects of antihypertensive agents. 
  • Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction. 
  • Multifactorial analysis of the learning curve for robot-assisted laparoscopic biliopancreatic diversion with duodenal switch. 
  • Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. 
  • Nutrition, education, and family physicians. 
  • Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. 
  • Oxidized low-density lipoprotein induces apoptosis in endothelial progenitor cells by inactivating the phosphoinositide 3-kinase/Akt pathway. 
  • Physical Activity as a Critical Component of First-Line Treatment for Elevated Blood Pressure or Cholesterol: Who, What, and How?: A Scientific Statement From the American Heart Association. 
  • Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. 
  • Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. 
  • Premature release of data from clinical trials of ezetimibe. 
  • Prevalence and risk factors of retinal arteriolar emboli: the Singapore Malay Eye Study. 
  • Prevalence and risk factors of retinal vein occlusion in an Asian population. 
  • Primary biliary cirrhosis: new therapeutic directions. 
  • Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. 
  • Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. 
  • Primary prevention of stroke. 
  • Prognostic models based on literature and individual patient data in logistic regression analysis. 
  • Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. 
  • RNA-targeted therapeutics in cardiovascular disease: the time is now. 
  • Recommendations of the Adult Treatment Panel of the National Cholesterol Education Program. Implications for the management of hypertension. 
  • Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. 
  • Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. 
  • Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? 
  • Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. 
  • Risk factor profile and management of cerebrovascular patients in the REACH Registry. 
  • Risk factors and preventive interventions for Alzheimer disease: state of the science. 
  • Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. 
  • Serious and actionable risks, plus disclosure: Investigating an alternative approach for presenting risk information in prescription drug television advertisements. 
  • Smooth muscle growth and cholesterol accumulation in atherogenesis. 
  • Spousal support in a behavior change intervention for cholesterol management. 
  • Spouse health behavior outcomes from a randomized controlled trial of a spouse-assisted lifestyle change intervention to improve patient low-density lipoprotein cholesterol. 
  • Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Statins after intracerebral hemorrhage: to treat or not to treat. 
  • Statins and cognition: what can we learn from existing randomized trials? 
  • Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. 
  • Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. 
  • Synergistic effects of exposure to concentrated ambient fine pollution particles and nitrogen dioxide in humans. 
  • Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering. 
  • Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. 
  • The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines. 
  • The dynamics of population aging: demography and policy analysis. 
  • The effect of hypercholesterolemia on early atherosclerotic lesions initiated by fibrinopeptide B. 
  • The healthy diver: A cross-sectional survey to evaluate the health status of recreational scuba diver members of Divers Alert Network (DAN). 
  • The relationship between albuminuria and hypercholesterolemia. 
  • Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. 
  • Universal Cholesterol Screening in Childhood: A Systematic Review. 
  • Use of alternative therapies in menopause. 
  • Vascular risk factors and cognitive decline among elderly male twins. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology